Regeneron announced on Friday that the Food and Drug Administration (FDA) is allowing a lower dose of its CCP virus treatment for injection. The approval comes as an update to the FDA’s emergency use authorization (EUA) for the company’s antibody cocktail to treat COVID-19, the disease caused by the CCP (Chinese Communist Party) virus. The treatment has been available under the EUA since last November for those recently diagnosed with COVID-19. The FDA had in November authorized a 2,400 mg dose of the antibody cocktail REGEN-COV—a combination of the monoclonal antibodies casirivimab and imdevimab—to be administered as a single dose directly injected to a vein for non-hospitalized COVID-19 patients. As part of the updated EUA, REGEN-COV is approved for injection “when IV infusion is not feasible and would lead to a delay in treatment.” The new dose authorized for both injection and IV infusion would be 1,200 mg (600 mg casirivimab and 600 mg …